Sanofi

Immunology + vaccines

SNY · Nasdaq · France

Share price · SNY

$47.12+2.15 (+4.78%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.3M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SNY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+2.7%
  2. 30 Oct 2026+2.8%
  3. 20 Oct 2026+4.6%
  4. 24 Sep 2026-1.7%
  5. 1 Jul 2026-2.4%
  6. 4 May 2026-5.9%
  7. 19 Mar 2026+3.7%
  8. 19 Feb 2026+2.7%
  9. 13 Feb 2026-2.2%
  10. 12 Feb 2026-4.5%

Share of unusual movement by asset

For each asset, the share of SNY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Aficamten (Myqorzo)
events and moves
1614%
dupilumab (Dupixent)
events and moves
275%
Isatuximab
events and moves
134%
Plozasiran (Redemplo)
events and moves
154%
Tolebrutinib
events and moves
113%
rilzabrutinib
events and moves
6shown from 8 days
Belumosudil
events and moves
3shown from 8 days
duvakitug
events and moves
2shown from 8 days
lunsekimig
events and moves
2shown from 8 days
Fitusiran (Qfitlia)
events and moves
2shown from 8 days
SAR341402
events and moves
1shown from 8 days
Venglustat (GZ/SAR402671)
events and moves
1shown from 8 days
SAR402663
events and moves
1shown from 8 days
SAR446597
events and moves
1shown from 8 days
insulin glargine (Lantus)
events and moves
1shown from 8 days
SAR448501
events and moves
1shown from 8 days
REGN20423
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—15%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—33%

Assets

(63 total)
63Total Assets
23Approved
7Phase 3 / Filed
33Phase 1–2 / Early
53Diseases
Quick filter:
Showing 63 of 63 assets
Target & Modality
Aficamten(Myqorzo)
Approved
Cardiac myosin (inhibitor)Small molecule
Hypertrophic Cardiomyopathy
Agalsidase beta(Fabrazyme)
Approved
Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic
Fabry Disease
Approved
CD52Monoclonal antibody
Multiple SclerosisChronic Lymphocytic Leukemia
Alirocumab(Praluent)
Approved
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia
Approved
Rho-associated kinase (ROCK, pan)Small molecule
Graft-versus-Host Disease
Chronic Graft-versus-Host Disease
Docetaxel(Taxotere)
Approved
Microtubules (tubulin)Small molecule
Non-Small Cell Lung CancerBreast CancerMetastatic Castration-Resistant Prostate CancerGastric CancerHead and Neck Squamous Cell CarcinomaProstate Cancer
HR+/HER2- Metastatic Breast Cancer
dupilumab(Dupixent)
Approved
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous UrticariaPrurigo NodularisEosinophilic Esophagitis
Fitusiran(Qfitlia)
Approved
Antithrombin (SERPINC1) mRNARNA / oligonucleotide
Hemophilia
Hemophilia A and B
glimepiride(Amaryl)
Approved
Sulfonylurea receptor (SUR1)Small molecule
Type 2 Diabetes
Glyburide(DiaBeta)
Approved
Sulfonylurea receptor (SUR1)Small molecule
Type 2 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptorPeptide
Type 2 DiabetesType 1 Diabetes
Approved
CD38Monoclonal antibody
Multiple Myeloma
Laronidase(ALDURAZYME)
Approved
Alpha-L-iduronidase (IDUA)Protein / enzyme therapeutic
Mucopolysaccharidosis Type I

Discontinued programmes (6)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(68 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
rilzabrutinibPhase 3Immune Thrombocytopenia
Est. primary completion 2026-11-25 · NCT07216079 · CT.gov ↗
What to watch
December 2026 (4)
SAR442970Phase 2Ulcerative Colitis
Est. primary completion 2026-12-17 · NCT06975722 · CT.gov ↗
What to watch
SAR442970Phase 2Crohn's Disease
Est. primary completion 2026-12-17 · NCT06958536 · CT.gov ↗
What to watch
rilzabrutinib + Frexalimab + SAR442970Phase 2Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Est. primary completion 2026-12-23 · NCT06500702 · CT.gov ↗
What to watch
Alirocumab · PraluentPhase 2Hypercholesterolemia
Est. primary completion 2026-12-29 · NCT07477704 · CT.gov ↗
What to watch
2027 (22)
January 2027 (1)
Daxokafusp alfaPhase 1/2Solid Tumor
Est. primary completion 2027-01-19 · NCT05584670 · CT.gov ↗
What to watch
February 2027 (2)
SAR442970Phase 2Hidradenitis Suppurativa
Est. primary completion 2027-02-09 · NCT07170917 · CT.gov ↗
What to watch
rilzabrutinibPhase 2Graves' Disease
Est. primary completion 2027-02-11 · NCT06984627 · CT.gov ↗
What to watch
March 2027 (2)
ROC-101Phase 2Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Est. primary completion 2027-03 · NCT07175038 · CT.gov ↗
What to watch
Fitusiran · QfitliaPhase 3Hemophilia
Est. primary completion 2027-03-25 · NCT05662319 · CT.gov ↗
What to watch
April 2027 (5)
IsatuximabPhase 2Plasma Cell Myeloma Refractory
Est. primary completion 2027-04-01 · NCT06356571 · CT.gov ↗
What to watch
IsatuximabPhase 3Plasma Cell Myeloma
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
SAR444336Phase 2Microscopic Colitis
Est. primary completion 2027-04-08 · NCT07156175 · CT.gov ↗
What to watch
FrexalimabPhase 2Type 1 Diabetes Mellitus
Est. primary completion 2027-04-28 · NCT06111586 · CT.gov ↗
What to watch
SAR442970Phase 2Type 1 Diabetes Mellitus
Est. primary completion 2027-04-29 · NCT06812988 · CT.gov ↗
What to watch
May 2027 (2)
FrexalimabPhase 3Multiple Sclerosis
Est. primary completion 2027-05-06 · NCT06141473 · CT.gov ↗
What to watch
SAR402663Phase 1/2Neovascular Age-related Macular Degeneration
Est. primary completion 2027-05-18 · NCT06660667 · CT.gov ↗
What to watch
June 2027 (2)
dupilumab · DupixentPhase 3Pruritus
Est. primary completion 2027-06-02 · NCT05263206 · CT.gov ↗
What to watch
lunsekimigPhase 2Asthma
Est. primary completion 2027-06-21 · NCT06676319 · CT.gov ↗
What to watch
July 2027 (3)
RiliprubartPhase 3Chronic Inflammatory Demyelinating Polyneuropathy
Est. primary completion 2027-07-09 · NCT06290141 · CT.gov ↗
What to watch
FrexalimabPhase 3Multiple Sclerosis
Est. primary completion 2027-07-15 · NCT07325292 · CT.gov ↗
What to watch
rilzabrutinibPhase 3Sickle Cell Disease
Est. primary completion 2027-07-23 · NCT06975865 · CT.gov ↗
What to watch
September 2027 (2)
Belumosudil + Isatuximab + Pegenzileukin + SAR439459Phase 1/2Plasma Cell Myeloma Refractory
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
SAR445399Phase 2Hidradenitis Suppurativa
Est. primary completion 2027-09-22 · NCT07225569 · CT.gov ↗
What to watch
October 2027 (2)
SAR446597Phase 1/2Geographic Atrophy
Est. primary completion 2027-10-13 · NCT07215234 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3Prurigo Nodularis
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (1)
rilzabrutinibPhase 3Immune Thrombocytopenia
Est. primary completion 2027-11-05 · NCT07007962 · CT.gov ↗
What to watch
2028 (16)
March 2028 (2)
SarilumabPhase 2Juvenile Idiopathic Arthritis
Est. primary completion 2028-03-01 · NCT02991469 · CT.gov ↗
What to watch
FrexalimabPhase 3Multiple Sclerosis
Est. primary completion 2028-03-24 · NCT06141486 · CT.gov ↗
What to watch
May 2028 (3)
dupilumab · DupixentPhase 3Dermatitis Atopic
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
duvakitugPhase 3Ulcerative Colitis
Est. primary completion 2028-05-09 · NCT07184996 · CT.gov ↗
What to watch
rilzabrutinibPhase 3Autoimmune Haemolytic Anaemia
Est. primary completion 2028-05-31 · NCT07086976 · CT.gov ↗
What to watch
June 2028 (3)
duvakitugPhase 2Hidradenitis
Est. primary completion 2028-06-16 · NCT07812116 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3Eosinophilic Esophagitis (EoE)
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
rilzabrutinibPhase 3Immunoglobulin G4 Related Disease
Est. primary completion 2028-06-28 · NCT07190196 · CT.gov ↗
What to watch
July 2028 (1)
Plozasiran · RedemploPhase 3Hypertriglyceridemia
Est. primary completion 2028-07 · NCT06822790 · CT.gov ↗
What to watch
August 2028 (1)
Daxokafusp alfaPhase 2Gastric Cancer, Oesophageal Carcinoma
Est. primary completion 2028-08-02 · NCT07692204 · CT.gov ↗
What to watch
September 2028 (3)
duvakitugPhase 3Ulcerative Colitis
Est. primary completion 2028-09-21 · NCT07185009 · CT.gov ↗
What to watch
BelumosudilPhase 2Chronic Graft Versus Host Disease
Est. primary completion 2028-09-25 · NCT07116031 · CT.gov ↗
What to watch
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2028-09-29 · NCT06143891 · CT.gov ↗
What to watch
October 2028 (1)
SarilumabPhase 1/2Rheumatoid Arthritis
Est. primary completion 2028-10-26 · NCT07704580 · CT.gov ↗
What to watch
November 2028 (1)
IsatuximabPhase 2Plasma Cell Myeloma
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (1)
dupilumab · DupixentPhase 3Wheezing, Asthma
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
2029 (16)
January 2029 (1)
BelumosudilPhase 3Lung Transplant Rejection
Est. primary completion 2029-01-29 · NCT06082037 · CT.gov ↗
What to watch
February 2029 (2)
lunsekimigPhase 2Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2029-02-22 · NCT06914908 · CT.gov ↗
What to watch
SAR446268Phase 1/2Myotonic Dystrophy
Est. primary completion 2029-02-28 · NCT06844214 · CT.gov ↗
What to watch
March 2029 (2)
Aficamten · MyqorzoPhase 2/3Symptomatic Hypertrophic Cardiomyopathy (HCM)
Est. primary completion 2029-03 · NCT04848506 · CT.gov ↗
What to watch
Plozasiran · RedemploPhase 3Severe Hypertriglyceridemia
Est. primary completion 2029-03 · NCT06880770 · CT.gov ↗
What to watch
April 2029 (1)
TolebrutinibPhase 3Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Est. primary completion 2029-04-30 · NCT06372145 · CT.gov ↗
What to watch
May 2029 (1)
duvakitugPhase 3Crohn's Disease
Est. primary completion 2029-05-14 · NCT07184931 · CT.gov ↗
What to watch
June 2029 (1)
SarilumabPhase 3Polymyalgia Rheumatica
Est. primary completion 2029-06-04 · NCT07286214 · CT.gov ↗
What to watch
July 2029 (1)
SAR448851Phase 2Dementia, Alzheimer's Type, Alzheimer's Disease
Est. primary completion 2029-07-31 · NCT07688213 · CT.gov ↗
What to watch
August 2029 (3)
Fitusiran · QfitliaPhase 3Hemophilia
Est. primary completion 2029-08-04 · NCT07285460 · CT.gov ↗
What to watch
duvakitugPhase 3Crohn's Disease
Est. primary completion 2029-08-13 · NCT07184944 · CT.gov ↗
What to watch
FrexalimabPhase 2/3Kidney Transplant Rejection
Est. primary completion 2029-08-15 · NCT07412470 · CT.gov ↗
What to watch
September 2029 (1)
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2029-09-14 · NCT07771439 · CT.gov ↗
What to watch
October 2029 (1)
RiliprubartPhase 3Polyneuropathy, Inflammatory Demyelinating, Chronic
Est. primary completion 2029-10-03 · NCT06859099 · CT.gov ↗
What to watch
November 2029 (2)
lunsekimigPhase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2029-11-27 · NCT07190209 · CT.gov ↗
What to watch
lunsekimigPhase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2029-11-27 · NCT07190222 · CT.gov ↗
What to watch
2030 (3)
January 2030 (2)
Aficamten · MyqorzoPhase 2/3Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2030-01 · NCT06412666 · CT.gov ↗
What to watch
Venglustat (GZ/SAR402671)Phase 3Gaucher's Disease Type III
Est. primary completion 2030-01-14 · NCT07927140 · CT.gov ↗
What to watch
October 2030 (1)
IsatuximabPhase 3Plasma Cell Myeloma
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch
2031 (3)
January 2031 (1)
lunsekimigPhase 2Asthma
Est. primary completion 2031-01-20 · NCT06609239 · CT.gov ↗
What to watch
May 2031 (1)
FrexalimabPhase 3Multiple Sclerosis
Est. primary completion 2031-05-16 · NCT07930624 · CT.gov ↗
What to watch
July 2031 (1)
lunsekimigPhase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2031-07-23 · NCT07793409 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
ElenestinibPhase 2/3Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Est. primary completion 2032-09-30 · NCT04910685 · CT.gov ↗
What to watch
2033 (1)
August 2033 (1)
SAR422459Phase 2Stargardt's Disease
Est. primary completion 2033-08-29 · NCT01736592 · CT.gov ↗
What to watch
2035 (1)
May 2035 (1)
rilzabrutinibPhase 2/3Immunodeficiency Common Variable
Est. primary completion 2035-05-10 · NCT07923305 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(35)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

25 November 2026FDA action dateVenglustat (GZ/SAR402671)PDUFA target action date set for venglustat
US, FDA · Source ↗

Recent

29 October 2026Topline resultSAR402663Interim Phase 1/2 results of SAR402663 (intravitreal gene therapy) in wet AMD presented at EURETINA 2026
Sanofi · Source ↗
22 July 2026Topline resultPlozasiranSHASTA-3 and SHASTA-4 topline: primary endpoint met
Arrowhead Pharmaceuticals · Source ↗
10 July 2026ApprovalIsatuximabFDA approves subcutaneous Sarclisa Escena with on-body injector
US, FDA · Source ↗
23 June 2026ApprovalTolebrutinibCenrifki (tolebrutinib) approved in the EU for nrSPMS
EU, EMA · Source ↗
22 June 2026ApprovalPlozasiranEC grants marketing authorization for REDEMPLO in FCS
EU, EMA · Source ↗
19 June 2026ApprovalIsatuximabSarclisa SC approved in Japan for multiple myeloma
JP, MHLW · Source ↗
8 June 2026ApprovalIsatuximabEU approval of Sarclisa subcutaneous via on-body injector
EU, European Commission · Source ↗
28 May 2026Priority reviewVenglustat (GZ/SAR402671)FDA grants priority review to venglustat NDA for GD3
US, FDA · Source ↗
28 May 2026Filing acceptedVenglustat (GZ/SAR402671)FDA accepts venglustat NDA for GD3
US, FDA · Source ↗
5 May 2026Topline resultAficamtenACACIA-HCM Phase 3 of aficamten in non-obstructive HCM met both dual primary endpoints
Cytokinetics · Source ↗
1 May 2026ApprovalPlozasiranTGA approves REDEMPLO (plozasiran) for FCS in Australia
AU, TGA · Source ↗
22 April 2026ApprovaldupilumabFDA approves Dupixent for CSU in children aged 2 to 11
US, FDA · Source ↗

The 12 most recent of 34 past events are shown.

Financial reports

Quarterly & interim (8)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$12.0B$2.0B$6.3B—report ↗
View 7 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4$13.2B$2.7B$9.0B—report ↗
2025-Q3$14.5B$2.1B$10.4B—report ↗
2025-Q2$11.3B$2.2B$18.0B—report ↗
2025-Q1$10.4B$1.9B$8.6B—report ↗
2024-Q4$11.3B$2.4B$7.7B—report ↗
2024-Q3$14.8B$2.0B——report ↗
2024-Q2$11.6B$1.8B$7.3B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$49.5B$8.9B$9.0B—report ↗

Sanofi reported FY2025 revenue of $49,451.93M, up 11.2% YoY, with R&D spend of $8,889.24M, up 11.1% YoY. Cash and equivalents stood at $9,002.03M, and the company recorded net income of $8,899.44M. No analyst expectations comparison was provided.

In business developments, Dupixent received approval in Japan as the first targeted medicine for adults with moderate-to-severe bullous pemphigoid, based on the LIBERTY-BP-ADEPT phase 2/3 study showing 18% of Dupixent patients achieved sustained disease remission versus 4% on placebo (p=0.0250); treatment-related adverse events occurred in 26% of Dupixent patients and 15% of placebo patients, with conjunctivitis the most common (4%). This is Dupixent’s seventh approved indication in Japan, and phase 3 studies continue in chronic pruritus of unknown origin and lichen simplex chronicus.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$44.5B$8.0B$7.7B—report ↗
2023-FY$46.6B$7.3B$9.6B—report ↗
2022-FY$45.3B$7.1B$13.6B—report ↗
2021-FY$44.7B$6.7B$11.4B—report ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 731 reporting institutions held 209.6M shares ($9.8B, 8.7% of shares outstanding).

#InstitutionSharesValue
1Dodge & Cox29,504,632$1.4B
2MORGAN STANLEY12,511,867$602.8M
3Fisher Asset Management, LLC11,442,163$551.3M
4BANK OF AMERICA CORP /DE/9,484,350$457.0M
5FRANKLIN RESOURCES INC7,165,193$345.2M
6Invesco Ltd.6,621,539$319.0M
7BARROW HANLEY MEWHINNEY & STRAUSS LLC5,887,466$283.7M
8JPMORGAN CHASE & CO5,600,731$261.7M
9Mondrian Investment Partners LTD5,040,065$242.8M
10FEDERATED HERMES, INC.4,754,359$229.1M
11FMR LLC4,010,161$193.2M
12ENVESTNET ASSET MANAGEMENT INC3,861,894$186.1M
13RAYMOND JAMES FINANCIAL INC3,812,745$183.7M
14BRANDES INVESTMENT PARTNERS, LP3,723,100$179.4M
15Boston Partners3,599,284$173.4M